1. Clin Infect Dis. 2014 Jan;58 Suppl 1:S51-7. doi: 10.1093/cid/cit618.

Tedizolid phosphate for the management of acute bacterial skin and skin structure
infections: safety summary.

Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P.

Author information: 
Cellular and Molecular Pharmacology.

The novel oxazolidinone tedizolid phosphate is in late-stage clinical
development. In an effort to improve efficacy and safety, the adverse event
profile and safety aspects of tedizolid phosphate have been evaluated in several 
preclinical animal models and through ongoing clinical trials. Early dose-ranging
studies demonstrated a favorable overall adverse event profile and low
thrombocytopenia rates, which have been consistently confirmed in phase 2 and 3
clinical trials. Pharmacokinetic modeling suggests a lower potential for
monoamine oxidase interaction, and animal and human subject testing has confirmed
these predictions. Studies in special patient populations showed a consistent and
predictable pharmacokinetic profile across age groups and comorbid conditions,
without evidence of increased incidence of adverse effects over matched controls.
The favorable safety profile makes tedizolid phosphate an important new option
for the management of serious Gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus.

PMID: 24343833  [PubMed - in process]